Survival study by organ disorders in 306 Japanese patients with systemic lupus erythematosus: results from a single center

被引:30
作者
Funauchi, M. [1 ]
Shimadzu, H. [1 ]
Tamaki, C. [1 ]
Yamagata, T. [1 ]
Nozaki, Y. [1 ]
Sugiyama, M. [1 ]
Ikoma, S. [1 ]
Kinoshita, K. [1 ]
机构
[1] Kinki Univ, Sch Med, Dept Nephrol & Rheumatol, Osaka 5898511, Japan
关键词
systemic lupus erythematosus; survival rate; organ disorders; neuropsychiatric disorder; renal disorder;
D O I
10.1007/s00296-006-0201-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Survival rate and causes of death according to the period of diagnosis and four accompanying organ disorders were analyzed in 306 Japanese patients with systemic lupus erythematosus. The survival rate was gradually improved, and the survival rate during 5- and 10-year periods of the patients diagnosed in 1990-2004 was 94 and 92%, 20-year period of those in 1980-1989 was 77%, 30-year period of those in 1975-1979 was 71%, respectively. Survival rate of those with serositis, pulmonary hypertension, and positive family history tended to be reduced, while that of the cases with neuropsychiatric disorder and renal disorder was significantly reduced. Overlapping of these organ disorders was an important factor for a poor prognosis. Bronchopneumonia and cerebrovascular accidents were frequent causes of death, and treatment for anti-phospholipid antibody syndrome and life-style diseases such as hypertension and arteriosclerosis was thought to be important for a good outcome.
引用
收藏
页码:243 / 249
页数:7
相关论文
共 30 条
[1]  
ABUSHAKRA M, 1995, J RHEUMATOL, V22, P1259
[2]   Long-term prognosis of antiphospholipid syndrome in patients with systemic lupus erythematosus [J].
Alarcón-Segovia, D ;
Pérez-Ruiz, A ;
Villa, AR .
JOURNAL OF AUTOIMMUNITY, 2000, 15 (02) :157-161
[3]  
ASHERSON RA, 1990, J RHEUMATOL, V17, P1292
[4]  
BIJORNADAL L, 2004, J RHEUMATOL, V31, P173
[5]   SYSTEMIC LUPUS-ERYTHEMATOSUS - EMERGING CONCEPTS .2. DERMATOLOGICAL AND JOINT DISEASE, THE ANTIPHOSPHOLIPID ANTIBODY SYNDROME, PREGNANCY AND HORMONAL-THERAPY, MORBIDITY AND MORTALITY, AND PATHOGENESIS [J].
BOUMPAS, DT ;
FESSLER, BJ ;
AUSTIN, HA ;
BALOW, JE ;
KLIPPEL, JH ;
LOCKSHIN, MD .
ANNALS OF INTERNAL MEDICINE, 1995, 123 (01) :42-53
[6]   Morbidity and mortality in systemic lupus erythematosus during a 10-year period -: A comparison of early and late manifestations in a cohort of 1,000 patients [J].
Cervera, R ;
Khamashta, MA ;
Font, J ;
Sebastiani, GD ;
Gil, A ;
Lavilla, P ;
Mejía, JC ;
Aydintug, AC ;
Chwalinska-Sadowska, H ;
de Ramón, E ;
Fernández-Nebro, A ;
Galeazzi, M ;
Valen, M ;
Mathieu, A ;
Houssiau, FD ;
Caro, N ;
Alba, P ;
Ramos-Casals, M ;
Ingelmo, M ;
Hughes, GRV .
MEDICINE, 2003, 82 (05) :299-308
[7]   Cardiovascular risk factors and the long-term outcome of lupus nephritis [J].
Font, J ;
Ramos-Casals, M ;
Cervera, R ;
García-Carrasco, M ;
Torras, A ;
Sisó, A ;
Darnell, A ;
Ingelmo, M .
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 2001, 94 (01) :19-26
[8]  
Gladman DD, 2003, J RHEUMATOL, V30, P1955
[9]   Outcome of silent lupus nephritis [J].
GonzalezCrespo, MR ;
LopezFernandez, JI ;
Usera, G ;
Poveda, MJ ;
GomezReino, JJ .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 1996, 26 (01) :468-476
[10]   Pulmonary hypertension in systemic lupus [J].
Johnson, SR ;
Gladman, DD ;
Urowitz, MB ;
Ibañez, D ;
Granton, JT .
LUPUS, 2004, 13 (07) :506-509